Stimuli-Responsive Biodegradable Nanoparticles for Targeted Drug Delivery

A biodegradable nanoparticle breaks open and releases its drug payload only when it encounters the high glutathione levels found inside cancer cells. Standard drug carriers often leak their contents before reaching the target, causing toxic side effects throughout the body. This project tackles that problem by building disulfide bonds into nanoparticles made from PLGA, a polymer already approved for medical use. Glutathione, a natural reducing agent that is far more concentrated inside tumour cells than in healthy tissue, snaps those bonds and triggers the particle to degrade. The researchers have shown that the particles degrade on cue, are non-toxic, and are readily taken up by cells. If this approach works in living systems, it could make chemotherapy far more selective. Patients would receive the same drug but with less damage to the heart, kidneys, and bone marrow. The same redox-triggered mechanism could also be adapted for other diseases where glutathione levels differ between healthy and diseased tissue. The work is still at the fundamental stage—the particles have been tested in cell cultures, not in animals or people—but it provides a clear chemical strategy for turning a biological difference into a therapeutic advantage.